Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (December 2021)
23 slides from Inspiremd's investor presentation, Dec 7, 2021
Slide 1: InspireMD
INSPIREM9
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: Investment Highlights
Investment Highlights MicroNet™ Proprietary Platform Technology Highly differentiated profile for treatment of carotid artery disease and stroke prevention clinicians Evidenced based / Clinically Supported JN CGuard™ EPS 8 clinical trials completed with >1,600 patient procedures and 3 ongoing clinic
Slide 4: Our Leadership
Our Leadership Marvin L. Slosman President and CEO INSPIREM9D Craig Shore Chief Financial Officer Bristol-Myers Squibb Andrea Tommasoli SVP Global Sales & Marketing INTEGRA C) Abbott T. JUDE M Boston Scientific = Universitates ii! BARCELONA ll Bellvitge | Hospital CBlerata
Slide 5: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE << —— 30% Surgical? 23% Surgical? 35% Surgical? 19% Surgical* \ \ \ \ Already have been c ed to endovascular proced 2 Bekelis K, Gottl
Slide 6: Stroke is the Second Biggest Cause of Death Globally
Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually* Top Two Causes of Death Globally (2020) 2 * 5 million deaths each year 10 9 * 5 million people left permanently disabled* ~ 8 8.86 27 ° $46 billion associated with stroke management § 6 ~
Slide 7: THE PROBLEM: Risks with Existing Approaches to CAD
THE PROBLEM: Risks with Existing Approaches to CAD Conventional approaches come with risks Carotid Endarterectomy (CEA) Risk of complications: Risk of complications: Myocardial infarction risk? (heart attack) Procedural and Cranial nerve injury risk? (vertigo, hearing loss, paralysis, etc) post-proc
Slide 8: THE PROBLEM: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS Post-Procedure with Conventional Stent Pre-Procedure 90% occlusion of | MRI of a pre-existing white Successful MRI reveals new multiple micro-infarcts the carotid artery _ matter infarction (obstruction) opening of the (obstructions) dug to li
Slide 9: Mechanics Translate to Clinical Results
Mechanics Translate to Clinical Results Pore size is an important differentiating factor in stent selection 45™ GEN Open Cell Stent 2ND GEN Closed Stent 4ST GEN Closed Cell Stent 3'd GEN Closed Stent CGuards’s Pore size opening is ~1/12 or 8.5% that of a conventional open cell stent INSPIREMD
Slide 10: OUR SOLUTION: Proprietary MicroNet Technology
OUR SOLUTION: Proprietary MicroNet™ Technology! plaque/tfiremibus esac ib ctween struts Conventional Open Cell Stent (15 GEN): Bare or dual layer approach, with plaque protrusion risk An Embolic Prevention System (EPS) for Ultimate Thrombus Protection MicroNet captures and locks thrombus & plaque ma
Slide 11: Carotid Solution: Our Well Studied Mesh-Covered Technology
Carotid Solution: Our Well Studied Mesh-Covered Technology More than patients in Clinical Publications & Studies INSPIREMD
Slide 12: Timeline Growth: From Alternative Stent to Potential New Gold Standard
Timeline Growth: From Alternative Stent to Potential New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS. CGUARD’S STANDING (known & anticipated) 2015 CARENET Safety, Efficacy & Neuroprotection over other stents data 2016 PARADIGM All comers population; Excellent clinical results (9) cua GENES lesin
Slide 13: CARENET Trial
CARENET Trial First in Man Study- Demonstrated Safety, Efficacy, & Neuroprotection over other stents data INSPIREM9D Clinical Support Highlights / Call out 2015-2021 PARADIGM Opened CARENET study inclusion criteria and concluded the safety and clinical outcomes were applicable to others outside of h
Slide 14: CGuard EPS Yields Superior Clinical Outcomes
CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard trends Superior 6.00% 5.00% 4.00% 3.00% 2.00% 1.00% 0.00% 1. IRONGUARD | Eurolntervention 2018 Nov 20. 14:1150-1152. 2. IRONGUARD II, LINC 2020 3. CASANA Eur J Vasc Endovasc Surg 2017 Dec.
Slide 15: Potential Multi Billion Dollar Market Opportunity
Potential Multi Billion Dollar Market Opportunity Our MicroNet™ covered stents like CGuard™ could become the new gold standard WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with CGuard™ ® Current addressable market: > $666 million
Slide 16: Commercial Footprint
Commercial Footprint Signed agreement with Chinese distributor. Working toward distribution U.S. Market Investigation Device Exemption (IDE) approval September 2020; US trial initiated Q3 2021 Exploring expansion opportunities Taiwan, Japan, and Korea WB current Markets uM GB Resistration Work Under
Slide 17: Growth Pathway to the U.S. Market
Growth Pathway to the U.S. Market U.S. Market Opportunity* Size: 155K High Grade Carotid Artery Stenosis (HGCS) interventions estimated in 2021 Opportunity: Ata price of $1,650 per stent, the addressable market is estimated to be approximately $317 million Executing and Funded Approval of FDA Premar
Slide 18: Our Lead Product, CGuard
Our Lead Product, CGuard™ Pre- and Post-Procedure with CGuard Cal a r \{ 26,000+ Total protected stents sold to date with excellent clinical results INSPIREM9D
Slide 19: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Our Key Value Drivers and Strategic Pathways + USA regulatory approval * China regulatory advancement CGuard Prime launch + Neuro Guard launch Asia Expansion * Commercial growth Chinese trial enrollment + Uplisting to NASDAQ + Significant fundraising USA reimburs
Slide 20: Our Robust Intellectual Property Portfolio
Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued | Allowed Pending USA 16 rl 6 Rest of World 37 1 6 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products INSPIREM9D
Slide 21: Summary Financials
Summary Financials December 3, 2021 NASDAQ Capital Markets NSPR Stock Price $3.29 Average 3 Month Volume 0.335M Shares Outstanding 8.3M Market Capitalization $27.3M Cash Balance - September 30*, 2021 $37.1M Debt $0M INSPIREMD
Slide 22: Our Board of Directors
Our Board of Directors Marvin L. Slosman President and CEO Paul Stuka Chairman Michael Berman Director Campbell Rogers, M.D. Director Thomas Kester Director Gary Roubin, M.D.,Ph.D. Director Katie Arnold Director INSPIREM9D Mr. Slosman has over 30 years of experience in the medical device industry wi
Slide 23: InspireMD
INSPIREMO NASDAQ = NSPR